NCT02698254
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Not Applicable
Drug Category: Radiation therapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain
Additional Notes: Patient must have received one & only one previous course of radiation to the brain; Patient must have been treated with radiation to the brain completed at least 6 months prior to the start of planned reirradiation
Exclusions: 
https://ClinicalTrials.gov/show/NCT02698254